This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Eptinezumab for prevention of Migraine

< Back

Eptinezumab for prevention of Migraine


Neurology and Neurosurgery

April 2020

Eptinezumab is a medicinal product currently in clinical development for the prevention of migraine. A migraine is usually a moderate or severe headache felt as a throbbing pain on one side of the head. Many people also have symptoms such as nausea, vomiting and increased sensitivity to light or sound. Migraines may be with aura (specific warning signs just before the migraine begins, such as seeing flashing lights), although the most common type is without aura (no specific warning signs).

Eptinezumab is a drug, which potentially reduces the occurrence of migraine by blocking the CGRP ligand (a protein) from attaching to, and activating its receptor; a process thought to be involved in migraine. In clinical trials, eptinezumab appears effective and well tolerated in the prevention of migraine. If licenced, eptinezumab will offer an additional option for the preventative treatment of migraine with or without aura in adults.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts